Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up

By Oh W.K.   Manola J.   Bittmann L.   Brufsky A.   Kaplan I.D.   Smith M.R.   Kaufman D.S.   Kantoff P.W.  

Urology, Vol. 62, Iss. 1, 2003-07 ,pp. : 99-104

Elsevier

Access to resources Recommend Favorite

Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate

By Brufsky A.   Fontaine-Rothe P.   Berlane K.   Rieker P.   Jiroutek M.   Kaplan I.   Kaufman D.   Kantoff P.  

Urology, Vol. 49, Iss. 6, 1997-06 ,pp. : 913-920

Elsevier

Access to resources Recommend Favorite

Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy

By Barqawi A.B.   Moul J.W.   Ziada A.   Handel L.   Crawford E.D.  

Urology, Vol. 62, Iss. 5, 2003-11 ,pp. : 872-876

Elsevier

Access to resources Recommend Favorite

Biochemical response to testicular androgen ablation among patients with prostate cancer for whom flutamide and/or finasteride therapy failed - a meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens

By Ornstein D.K.   Smith D.S.   Andriole G.L.  

Urology, Vol. 52, Iss. 6, 1998-12 ,pp. : 1094-1097

Elsevier

Access to resources Recommend Favorite

A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer

By Schellhammer P.   Sharifi R.   Block N.   Soloway M.   Venner P.   Patterson A.L.   Sarosdy M.   Vogelzang N.   Jones J.   Kolvenbag G.  

Urology, Vol. 45, Iss. 5, 1995-05 ,pp. : 745-752

Elsevier

Access to resources Recommend Favorite